AbbVie to Acquire Pharmacyclics: What it Means For Mutual Fund Investors (ABBV, PCYC)

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

Abbvie company logo

News

AbbVie to Acquire Pharmacyclics: What it Means For Mutual Fund Investors (ABBV, PCYC)

Shauna O'Brien Mar 05, 2015

Before the opening bell on Thursday, drug company AbbVie (ABBV) announced that it has agreed to acquire Pharmacyclics (PCYC). Here’s what this deal means for mutual fund investors.

Inside the Deal

AbbVie will acquire Pharmacyclics, a biotechnology company that specializes in cancer drugs for about $21 billion. This deal, which is expected to close in the middle of 2015, will be composed of 58% cash, and 42% of ABBV’s common stock. In the deal, ABBV will acquire Pharmacyclics for $261.25 per share.

This is the first deal that the company has made since its terminated deal to acquire Ireland-based Shire.

Shares of ABBV dropped 2.5% on the news, while PCYC sales surged over 10%.


AbbVie’s Drug Pipeline

AbbVie, which spun off from Abbott (ABT) in 2012, currently has over 40 drugs in its pipeline. This deal will give ABBV exposure to the blood-cancer market and allow it to add even more drugs to its product line.

Despite the opportunity, shares of ABBV are down today, as many analysts see PCYC’s Imbruvica drug as unable to meet ambitious sales estimates.


Mutual Funds to Watch

Investors interested in ABBV may consider a mutual fund as an alternative to owning the individual stock. The funds below currently hold the largest stakes in ABBV.

The Bottom Line

The funds listed above allow investors to gain exposure to ABBV while remaining diversified. Investors interested in ABBV may also be interested in Abbott (ABT) or Pfizer (PFE).

If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.


Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Popular Articles

Download Our Free Report

Why 30 trillion is invested in mutual funds book